Article citationsMore>>

Glehen, O., Gilly, F.N., Boutitie, F., Bereder, J.M., Quenet, F., Sideris, L., Mansvelt, B., Lorimier, G., Msika, S. and Elias, D. (2010) Toward curative treatment of peritoneal carcinomatosis from nonovarian origin by cytoreductive surgery combined with perioperative intraperitoneal chemotherapy: A multi-institutional study of 1290 patients. Cancer, 116, 5608-5618.
http://dx.doi.org/10.1002/cncr.25356

has been cited by the following article:

• TITLE: Intraperitoneal distribution of alginate microcapsules in mice

  AUTHORS: F. Dagbert, Y. J. McConnell, E. Carmona, L. Sideris, J. P. Hallé, P. Dube

  KEYWORDS: Alginate Microcapsule; Peritoneal Cavity; Peritoneal Carcinosis; Thymidine Phosphorylase; HIPEC; Capecitabine

  JOURNAL NAME: Modern Chemotherapy, Vol.3 No.1, January 24, 2014

  ABSTRACT: Introduction: Improved drug delivery mechanisms for the treatment of residual peritoneal cancer cells following cytoreduction surgery are needed. Alginate microcapsules are a potentially useful mechanism for delivery of bioengineered cells, but when injected into the peritoneum, their distribution and properties are not well described. Methods: Aliquots of 300, 600 or 1200 microcapsules were injected into the peritoneum of 81 mice. Mice were sacrificed at 6, 12, 18, and 48 days and laparotomy was performed to quantify the distribution of microspheres. Results: The injections were well tolerated for up to 48 days. No peritoneal adherence or inflammatory reaction was noted to the microcapsules. Injection of 1200 microcapsules resulted in a better overall persistence and widespread peritoneal distribution at up to 48 days. The volume of fluid used for injection of the microcapsules did not affect their distribution or persistence. Conclusion: The intraperitoneal injection of alginate microspheres allows wide and persistent distribution throughout the abdominal cavity. The next step is to test the distribution of microcapsules when delivered following surgery in a rodent model.